Corresponding Author: William D. Leslie, MD, MSc, Department of Medicine (C5121), University of Manitoba, 409 Tache Ave, Winnipeg, MB R2H 2A6, Canada (bleslie@sbgh.mb.ca).
Author Contributions: Dr Leslie had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.
Study concept and design: Leslie, Morin, Hanley.
Acquisition of data: Leslie, O’Donnell, Walsh, Bancej.
Analysis and interpretation of data: Leslie, O’Donnell, Jean, Lagacé, Walsh, Bancej, Hanley, Papaioannou.
Drafting of the manuscript: Leslie.
Critical revision of the manuscript for important intellectual content: Leslie, O’Donnell, Jean, Lagacé, Walsh, Bancej, Morin, Hanley, Papaioannou.
Statistical analysis: Leslie, Jean, Walsh.
Administrative, technical, or material support: Leslie, O’Donnell, Lagacé, Bancej, Papaioannou.
Study supervision: Morin.
Financial Disclosures: Dr Leslie reported receiving honoraria for lectures from Merck Frosst Canada; research support from Merck Frosst Canada and Amgen Pharmaceuticals Canada; and unrestricted educational and research grants from the Alliance for Better Bone Health, Sanofi-Aventis, Procter & Gamble Pharmaceuticals Canada, Genzyme Canada, and Amgen Pharmaceuticals Canada. Dr Morin reported serving on advisory boards for Procter & Gamble, Sanofi-Aventis, Servier, Amgen, Eli Lilly, and Novartis; serving on the speakers' bureau for Procter & Gamble, Sanofi-Aventis, and Servier; and receiving an unrestricted research grant from Amgen. Dr Hanley reported serving on advisory boards for Amgen Canada, Eli Lilly Canada, Merck Frosst Canada, Novartis Canada, NPS Pharmaceuticals, Nycomed, Procter & Gamble Canada; working on clinical trials for Amgen, Aventis, Eli Lilly Canada, Merck Frosst, Novartis, NPS Pharmaceuticals, Pfizer, Procter & Gamble, Roche, Wyeth-Ayerst; and receiving speaking honoraria from Amgen, Aventis, Eli Lilly Canada, Merck Frosst, Novartis, NPS Pharmaceuticals, Nycomed, Procter & Gamble Canada, and Wyeth-Ayerst. Dr Papaioannou reported serving as a consultant or on the speakers' bureau for Amgen, Aventis Pharma, Eli Lilly, Merck Frosst Canada, Novartis, Procter & Gamble Pharmaceuticals, Servier, and Wyeth-Ayerst; working on clinical trials for Eli Lilly, Merck Frosst, Novartis, Procter & Gamble, and Sanofi-Aventis; receiving unrestricted grants from Amgen, Eli Lilly, Merck Frosst, Procter & Gamble, and Sanofi-Aventis; and receiving other support from the Ontario Ministry of Health and Long Term Care.
Osteoporosis Surveillance Expert Working Group: Jacques Brown, MD, Laval University, Quebec City, Quebec, Canada; Ann Cranney, MD, MSc, University of Ottawa, Ottawa, Ontario, Canada; David A. Hanley, MD, University of Calgary, Calgary, Alberta, Canada; Susan Jaglal, PhD, University of Toronto, Toronto, Ontario, Canada; Sonia Jean, MSc, Institut National de Santé Publique du Québec, Quebec City; Famida Jiwa, MHSC, DC, Osteoporosis Canada, Toronto; Stephanie Kaiser, MD, Dalhousie University, Halifax, Nova Scotia, Canada; David L. Kendler, MD, Prohealth Clinical Research Centre, Vancouver, British Columbia, Canada; William D. Leslie, MD, MSc, University of Manitoba, Winnipeg, Canada; Suzanne Morin, MD, MSc, McGill University, Montreal, Quebec, Canada; Alexandra Papaioannou, MD, MSc, McMaster University, Hamilton, Ontario, Canada; Kerry Siminoski, MD, University of Alberta, Edmonton.
Disclaimer: The analyses and conclusions in this report reflect the opinions of individual experts and not their affiliated organizations.